Suppr超能文献

NDM-1 的分子基础,一种新的抗生素耐药决定簇。

Molecular basis of NDM-1, a new antibiotic resistance determinant.

机构信息

Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.

出版信息

PLoS One. 2011;6(8):e23606. doi: 10.1371/journal.pone.0023606. Epub 2011 Aug 24.

Abstract

The New Delhi Metallo-β-lactamase (NDM-1) was first reported in 2009 in a Swedish patient. A recent study reported that Klebsiella pneumonia NDM-1 positive strain or Escherichia coli NDM-1 positive strain was highly resistant to all antibiotics tested except tigecycline and colistin. These can no longer be relied on to treat infections and therefore, NDM-1 now becomes potentially a major global health threat.In this study, we performed modeling studies to obtain its 3D structure and NDM-1/antibiotics complex. It revealed that the hydrolytic mechanisms are highly conserved. In addition, the detailed analysis indicates that the more flexible and hydrophobic loop1, together with the evolution of more positive-charged loop2 leads to NDM-1 positive strain more potent and extensive in antibiotics resistance compared with other MBLs. Furthermore, through biological experiments, we revealed the molecular basis for antibiotics catalysis of NDM-1 on the enzymatic level. We found that NDM-1 enzyme was highly potent to degrade carbapenem antibiotics, while mostly susceptible to tigecycline, which had the ability to slow down the hydrolysis velocity of meropenem by NDM-1. Meanwhile, the mutagenesis experiments, including D124A, C208A, K211A and K211E, which displayed down-regulation on meropenem catalysis, proved the accuracy of our model.At present, there are no effective antibiotics against NDM-1 positive pathogen. Our study will provide clues to investigate the molecular basis of extended antibiotics resistance of NDM-1 and then accelerate the search for new antibiotics against NDM-1 positive strain in clinical studies.

摘要

新德里金属β-内酰胺酶(NDM-1)于 2009 年在瑞典患者中首次报道。最近的一项研究报告称,肺炎克雷伯菌 NDM-1 阳性株或大肠埃希菌 NDM-1 阳性株对除替加环素和黏菌素以外的所有测试抗生素均高度耐药。这些药物已不能再用于治疗感染,因此,NDM-1 现在可能成为一个主要的全球健康威胁。在这项研究中,我们进行了建模研究以获得其 3D 结构和 NDM-1/抗生素复合物。结果表明,水解机制高度保守。此外,详细分析表明,更灵活和疏水性环 1 以及环 2 上更多正电荷的进化导致 NDM-1 阳性株比其他 MBL 对抗生素具有更强和更广泛的耐药性。此外,通过生物学实验,我们在酶学水平上揭示了 NDM-1 对抗生素催化的分子基础。我们发现 NDM-1 酶对碳青霉烯类抗生素具有很强的降解能力,而对替加环素的敏感性较高,替加环素能够减缓 NDM-1 对美罗培南的水解速度。同时,包括 D124A、C208A、K211A 和 K211E 在内的突变实验,这些实验显示对美罗培南催化的下调,证明了我们模型的准确性。目前,还没有针对 NDM-1 阳性病原体的有效抗生素。我们的研究将为研究 NDM-1 广泛耐药的分子基础提供线索,然后加速在临床研究中寻找针对 NDM-1 阳性株的新抗生素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7def/3161043/e80a92c0681e/pone.0023606.g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验